🍽️ fludarabine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antineoplastic Activity: Fludarabine is a purine analog that interferes with the DNA synthesis process in cancer cells, leading to cell cycle arrest and ultimately cell death. It is primarily used as a cytotoxic agent to target and destroy cancer cells, thereby inhibiting tumor growth and proliferation.

  2. Treatment of Chronic Lymphocytic Leukemia (CLL): Fludarabine is commonly used as a first-line or salvage therapy for CLL, a type of leukemia characterized by the accumulation of abnormal lymphocytes in the blood and bone marrow. It helps induce remission and improve survival rates in patients with CLL.

  3. Treatment of Non-Hodgkin Lymphoma (NHL): Fludarabine is also used in the treatment of certain types of NHL, including follicular lymphoma and mantle cell lymphoma. It may be used alone or in combination with other chemotherapy drugs or monoclonal antibodies to improve treatment outcomes.

  4. Treatment of Acute Myeloid Leukemia (AML): In some cases, fludarabine may be used in combination with other chemotherapy agents as part of induction therapy or consolidation therapy for AML, particularly in patients who are not candidates for intensive chemotherapy regimens.

  5. Dosage and Administration: Fludarabine is typically administered intravenously (IV) over a period of several days, either as a single agent or in combination with other chemotherapy drugs. The dosage and treatment schedule vary depending on the specific type and stage of cancer being treated, as well as the patient's overall health and tolerance to therapy.

  6. Side Effects: Common side effects of fludarabine may include bone marrow suppression (leading to neutropenia, anemia, and thrombocytopenia), increased susceptibility to infections, nausea, vomiting, diarrhea, fatigue, fever, headache, rash, and hair loss (alopecia). These side effects are usually temporary and reversible once treatment is completed.

  7. Immunosuppression: Fludarabine can cause significant immunosuppression, which may increase the risk of infections, including opportunistic infections. Patients receiving fludarabine should be closely monitored for signs of infection, and prophylactic antibiotics or antiviral medications may be prescribed to prevent infections.

  8. Hematologic Toxicity: Fludarabine can suppress the production of blood cells in the bone marrow, leading to a decrease in white blood cells, red blood cells, and platelets. This may result in an increased risk of bleeding, anemia, and compromised immune function.

  9. Long-Term Effects: Long-term use of fludarabine may be associated with an increased risk of secondary malignancies, such as myelodysplastic syndrome (MDS) or acute leukemia. Regular monitoring and follow-up care are important for detecting and managing any potential long-term complications of treatment.

  10. Contraindications and Precautions: Fludarabine is contraindicated in patients with known hypersensitivity to the drug or its components. It should be used with caution in patients with pre-existing bone marrow suppression, renal impairment, or hepatic dysfunction. Pregnant women should avoid fludarabine due to its potential teratogenic effects on the fetus.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of fludarabine,(prescription) On Probiotics

Rank Probiotic Impact
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces

Bacteria Impacted by fludarabine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Clostridium genus Decreases 👪 Source Study Pathogen
Escherichia genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Lacticaseibacillus genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Escherichia coli O55:H7 no rank Decreases 👶 Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O126:H45 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O145:NM serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O167:H26 serotype Decreases 👶 Source Study
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O6:K2:H1 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Escherichia coli O78:H4 serotype Decreases 👶 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Roseburia intestinalis species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study

Impact of fludarabine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0 0
ADHD 0.3 0.3
Age-Related Macular Degeneration and Glaucoma 0.2 0.1 1
Allergic Rhinitis (Hay Fever) 1.3 1.3
Allergies 1.3 0.5 1.6
Allergy to milk products 1.6 0.6 1.67
Alopecia (Hair Loss) 0.2 0.2
Alzheimer's disease 1.3 1.4 -0.08
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.9 0.9 0
Ankylosing spondylitis 1.5 0.2 6.5
Anorexia Nervosa 0.1 0.9 -8
Antiphospholipid syndrome (APS) 1.2 0 0
Asthma 0.5 0.4 0.25
Atherosclerosis 1 -1
Atrial fibrillation 0.3 0.8 -1.67
Autism 2.4 1.9 0.26
benign prostatic hyperplasia 0.4 0.4
Biofilm 0.9 0.9
Bipolar Disorder 0.8 0.2 3
Brain Trauma 0.4 -0.4
Cancer (General) 1.1 -1.1
Carcinoma 0.8 0.3 1.67
Celiac Disease 1.1 0.4 1.75
Cerebral Palsy 0.5 0.4 0.25
Chronic Fatigue Syndrome 1.7 0.5 2.4
Chronic Kidney Disease 0.8 0.2 3
Chronic Lyme 0.4 -0.4
Chronic Obstructive Pulmonary Disease (COPD) 0.2 -0.2
Chronic Urticaria (Hives) 1.8 0.4 3.5
Coagulation / Micro clot triggering bacteria 1.4 0.2 6
Colorectal Cancer 2.3 2.3
Constipation 0.7 0.2 2.5
COVID-19 2.1 0.7 2
Crohn's Disease 2.8 0.9 2.11
cystic fibrosis 1.3 0.4 2.25
deep vein thrombosis 1.3 0.2 5.5
Depression 2.2 1.5 0.47
Eczema 0.4 0.9 -1.25
Endometriosis 1.7 1.7
Epilepsy 1.1 0.3 2.67
Fibromyalgia 0.8 0.7 0.14
Functional constipation / chronic idiopathic constipation 2.9 1.3 1.23
gallstone disease (gsd) 1 0.2 4
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.4 0.4
Generalized anxiety disorder 1.3 0.7 0.86
giant cell arteritis 0.5 -0.5
Graves' disease 0.3 0.2 0.5
Halitosis 0.2 0.2
Hashimoto's thyroiditis 0.4 0.3 0.33
Hidradenitis Suppurativa 0 0
High Histamine/low DAO 2.5 2.5
hypercholesterolemia (High Cholesterol) 0.5 0.5
hyperglycemia 0.4 0.3 0.33
hypersomnia 0 0
hypertension (High Blood Pressure 0.8 0.9 -0.13
Hypoxia 0.3 0.3
IgA nephropathy (IgAN) 0.5 -0.5
Inflammatory Bowel Disease 2 1.9 0.05
Insomnia 0.2 0.4 -1
Intelligence 0.5 0.5
Intracranial aneurysms 0.3 0.3
Irritable Bowel Syndrome 2.2 0.5 3.4
Liver Cirrhosis 1.5 0.9 0.67
Long COVID 0.8 0.5 0.6
Low bone mineral density 0.2 -0.2
Lung Cancer 0.4 0.4
Mast Cell Issues / mastitis 0.4 0.4
ME/CFS with IBS 0.5 0.2 1.5
ME/CFS without IBS 0.5 0.4 0.25
Metabolic Syndrome 2.8 1.5 0.87
Mood Disorders 3.2 1.5 1.13
Multiple Sclerosis 0.2 2.6 -12
neuropathic pain 0.2 -0.2
Neuropathy (all types) 0.4 -0.4
neuropsychiatric disorders (PANDAS, PANS) 0.9 0.9
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.9 0.2 3.5
NonCeliac Gluten Sensitivity 0.2 -0.2
Obesity 1.5 0.4 2.75
obsessive-compulsive disorder 2.1 0.2 9.5
Osteoarthritis 1.2 1.2
Osteoporosis 1.2 0.2 5
Parkinson's Disease 2.6 1.9 0.37
Polycystic ovary syndrome 1.3 0.6 1.17
Postural orthostatic tachycardia syndrome 0.5 0.5
Premenstrual dysphoric disorder 0.1 -0.1
Psoriasis 1.8 0.7 1.57
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1 1.3 -0.3
Rosacea 0.6 -0.6
Schizophrenia 1.8 0.6 2
scoliosis 0 0
Sjögren syndrome 0.6 0.3 1
Sleep Apnea 0.4 -0.4
Slow gastric motility / Gastroparesis 1.1 1.1
Small Intestinal Bacterial Overgrowth (SIBO) 0.9 0.9
Stress / posttraumatic stress disorder 1.9 0.4 3.75
Systemic Lupus Erythematosus 1.3 0.2 5.5
Tourette syndrome 0.2 -0.2
Type 1 Diabetes 1.2 0.6 1
Type 2 Diabetes 2.3 2.3 0
Ulcerative colitis 2.1 1 1.1
Unhealthy Ageing 0.7 0.2 2.5
Vitiligo 0.4 0.6 -0.5

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [35.170.81 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.170.81 ]